AR052641A1 - Uso de acido docosahexaenoico (dha) y acido araquidonico (ara) para la manufactura de un medicamento para la prevencion o tratamiento de infecciones respiratorias en infantes - Google Patents

Uso de acido docosahexaenoico (dha) y acido araquidonico (ara) para la manufactura de un medicamento para la prevencion o tratamiento de infecciones respiratorias en infantes

Info

Publication number
AR052641A1
AR052641A1 ARP050103604A ARP050103604A AR052641A1 AR 052641 A1 AR052641 A1 AR 052641A1 AR P050103604 A ARP050103604 A AR P050103604A AR P050103604 A ARP050103604 A AR P050103604A AR 052641 A1 AR052641 A1 AR 052641A1
Authority
AR
Argentina
Prior art keywords
dha
ara
manufacture
children
prevention
Prior art date
Application number
ARP050103604A
Other languages
English (en)
Inventor
Carlos H Lifschitz
Nitida Pastor
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR052641A1 publication Critical patent/AR052641A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Pediatric Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Uso de una cantidad terapéuticamente efectiva de DHA y ARA para la manufactura de un medicamento para prevenir o tratar las infecciones respiratorias en los infantes.
ARP050103604A 2005-04-07 2005-08-29 Uso de acido docosahexaenoico (dha) y acido araquidonico (ara) para la manufactura de un medicamento para la prevencion o tratamiento de infecciones respiratorias en infantes AR052641A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66911105P 2005-04-07 2005-04-07
US11/114,892 US20060229366A1 (en) 2005-04-07 2005-04-26 Method for preventing or treating respiratory infections in infants

Publications (1)

Publication Number Publication Date
AR052641A1 true AR052641A1 (es) 2007-03-28

Family

ID=35432875

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103604A AR052641A1 (es) 2005-04-07 2005-08-29 Uso de acido docosahexaenoico (dha) y acido araquidonico (ara) para la manufactura de un medicamento para la prevencion o tratamiento de infecciones respiratorias en infantes

Country Status (14)

Country Link
US (1) US20060229366A1 (es)
EP (1) EP1709961A1 (es)
KR (1) KR20060106583A (es)
AR (1) AR052641A1 (es)
BR (1) BRPI0503827A (es)
CA (1) CA2516873A1 (es)
CO (1) CO5750041A1 (es)
IN (1) IN2006CH00621A (es)
MX (1) MXPA05009927A (es)
NO (1) NO20055079L (es)
PA (1) PA8649001A1 (es)
RU (1) RU2005130292A (es)
SG (1) SG126810A1 (es)
TW (1) TW200635574A (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2488283C2 (ru) * 2007-11-01 2013-07-27 Энзимотек Лтд. Липидная смесь для детского питания
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
WO2012012498A2 (en) * 2010-07-20 2012-01-26 Pulmatrix, Inc. Use of trp channel agonists to treat infections
CA2812414C (en) 2010-09-29 2020-09-22 Pulmatrix, Inc. Monovalent metal cation dry powders for inhalation
MX2015013845A (es) 2013-04-01 2016-05-09 Pulmatrix Inc Polvos secos de tiotropio.
WO2022226311A1 (en) * 2021-04-23 2022-10-27 Abbott Laboratories Nutritional compositions comprising human milk oligosaccharides and a designed lipid component for improving lung function

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407957A (en) 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
WO1992012711A1 (en) 1991-01-24 1992-08-06 Martek Corporation Microbial oil mixtures and uses thereof
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
WO1998044917A1 (en) * 1997-03-27 1998-10-15 Bristol-Myers Squibb Company Use of docosahexanoic acid and arachidonic acid enhancing the growth of preterm infants
US6180671B1 (en) * 1998-03-10 2001-01-30 Beth Israel Deaconess Medical Center, Inc. Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected
US20040143013A1 (en) * 2000-02-28 2004-07-22 Bristol-Myers Squibb Company Use of docosahexaenoic acid and arachidonic acid enhancing the growth of preterm infants
DE602004006258T3 (de) * 2004-08-24 2013-08-29 Nutricia N.V. Nahrungszusammensetzung die unverdauliche Transgalaktooligosaccharide sowie verdauliche Galaktose-Saccharide enthält

Also Published As

Publication number Publication date
RU2005130292A (ru) 2007-04-10
US20060229366A1 (en) 2006-10-12
NO20055079L (no) 2006-10-09
KR20060106583A (ko) 2006-10-12
BRPI0503827A (pt) 2006-12-19
MXPA05009927A (es) 2006-10-01
CA2516873A1 (en) 2006-10-07
TW200635574A (en) 2006-10-16
EP1709961A1 (en) 2006-10-11
IN2006CH00621A (es) 2007-06-15
CO5750041A1 (es) 2007-04-30
SG126810A1 (en) 2006-11-29
NO20055079D0 (no) 2005-10-31
PA8649001A1 (es) 2006-10-13

Similar Documents

Publication Publication Date Title
CY1122628T1 (el) Χρηση αιθυλεστερα εικοσαπενταενοϊκου οξεος για θεραπεια υπερτριγλυκεριδαιμιας
NO20092527L (no) Prolegemidler, fremgangsmate for fremstilling og anvendelse derav
CY1110133T1 (el) Θεραπευτικος παραγων υπερλιπαιμιας που περιλαμβανει πιταβαστατινες και εικοσαπενταενοϊκο οξυ
AR070047A1 (es) Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog.
AR052641A1 (es) Uso de acido docosahexaenoico (dha) y acido araquidonico (ara) para la manufactura de un medicamento para la prevencion o tratamiento de infecciones respiratorias en infantes
NO20083187L (no) Anvendelse av DHA, EPA eller DHA-avledet EPA til behandling av patologi assosiert med cellulaer oksidativ skade
DK1970059T3 (da) Lægemiddel med calciumdobesilat til behandling og profylakse af senelidelser
UY31609A1 (es) "(-) ácido 2-[1-(7-metil-2-(morfolin-4-il) 4-oxo-4h-pirido[1,2-a]pirimidin-9-il)etilamino]benzoico enantioméricamente puro, su uso en terapia médica, y una composición farmacéutica que lo comprende-026."
AR058679A1 (es) Preparacion farmaceutica que contiene meloxicam
UY32989A (es) Coposiciones terapéuticas concentradas de fosfolípidos
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
NO20065915L (no) Forbedring av barriereintegritet i HIV-pasienter
AR075369A1 (es) Comprimidos para terapia de combinacion para el tratamiento de infecciones virales.
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
DK2043637T3 (da) Fremgangsmåder og medikamenter til administrering af ibuprofen
CO6592015A2 (es) Métodos y composiciones para reducir o prevenir la cladificación vascular durante el tratamiento de diálisis peritoneal
AR087003A1 (es) Dispositivo separador modular para el tratamiento de infecciones de la protesis de miembros humanos
AR072951A1 (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
GT200800235A (es) Formulacion de medicamento liquida
AR074246A1 (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno
ECSP066836A (es) Piperazinas derivadas de úrea para el tratamiento de la endometrosis
DOP2005000170A (es) Metodo de prevencion o tratamiento de infeciones respiratorias en infantes
AR061046A1 (es) Mirtazapina para el tratamiento del dolor neuropatico
DE602007009986D1 (de) Nanostrukturierte lipidträger mit riluzol und diese teilchen enthaltende pharmazeutische formulierungen
IT1396649B1 (it) Preparazioni farmaceutiche comprendenti floroglucinolo e/o suoi derivati e farmaci anti-infiammatori non steroidi e loro uso nel trattamento e/o nella prevenzione delle sindromi dolorose dell'apparato genitale femminile.

Legal Events

Date Code Title Description
FB Suspension of granting procedure